IPOs
Filter News
Found 17,180 articles
-
Contineum Therapeutics joined the 2024 initial public offering class on Friday with an SEC filing. The biotech will use the IPO proceeds to complete a Phase II trial for its most mature candidate targeting multiple sclerosis.
-
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
3/18/2024
Elicio Therapeutics, Inc. announced today that it has entered into a subscription agreement to sell pre-funded warrants to purchase up to 1,032,702 shares of its common stock at a purchase price of $5.81 per pre-funded warrant.
-
Spyre Therapeutics Announces $180 Million Private Placement - March 18, 2024
3/18/2024
Spyre Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses.
-
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
3/18/2024
Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin").
-
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
3/18/2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") today Announced that its Board of Directors (Board) has authorized its Chairman and management to take all necessary steps to affect a Dividend of HOPE Therapeutics.
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 15, 2024
3/15/2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units (“RSUs”) to three new employees under Acadia’s 2023 Inducement Plan.
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 15, 2024
3/15/2024
Scholar Rock today announced that the company granted inducement equity awards on March 11, 2024, covering an aggregate of 201,469 shares of its common stock to six newly hired employees.
-
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares
3/15/2024
Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq Stock Market.
-
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
3/15/2024
Avenue Therapeutics, Inc. today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.
-
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
3/14/2024
180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).
-
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
3/12/2024
Outlook Therapeutics, Inc. today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective on March 14, 2024.
-
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
3/12/2024
T2 Biosystems, Inc. today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on the Nasdaq Stock Market.
-
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
3/11/2024
Dyadic International, Inc. announced today that it entered into a securities purchase agreement on March 8, 2024, pursuant to which, the Company has sold and issued an aggregate principal amount of $6.0 million of its 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027.
-
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
3/11/2024
Intelligent Bio Solutions Inc. today announced that on March 8, 2024, it entered into securities purchase agreements with several healthcare-focused institutional and accredited investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,223,333 shares of common stock.
-
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 8, 2024
3/8/2024
UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) to 12 new employees in connection with their employment with UroGen.
-
The early-stage oncology startup filed for an initial public offering on Wednesday, seeking funds to help develop its novel cancer therapies targeting extrachromosomal DNA.
-
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
3/7/2024
Ventyx Biosciences, Inc. announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share.
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2024
3/6/2024
Fusion Pharmaceuticals Inc. today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 245,300 shares.
-
Companies inked 204 deals in the fourth quarter of 2023 with venture capital funding slipping to $6.3 billion from $7.8 billion in the third quarter last year, according to market data firm Pitchbook.
-
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
3/5/2024
Quoin Pharmaceuticals Ltd. today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to 4,062,500 ordinary shares.